For the treatment of Sjorgens’s Syndrome, sometime people manage the treatment using through OTC drug, counter eye drop and but for serious issue prescription drug or surgical procedure is needed.
People with Sjogren’s develop more severe inflammation, involving organs such as the kidneys, lungs, intestines, or brain. For these people, physician may prescribe more aggressive medications such as Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.
The global Sjogren’s syndrome market is estimated to be valued at US$ 234.6 million in 2022 and expected to exhibit a CAGR of 3.5% over the forecast period (2022-2030).
Figure 1. Global Sjogren’s syndrome Market Share (%) in Terms of Value, by Region, 2022
Increasing robust pipeline of drug is expected to aid in the growth of the global Sjogren’s syndrome market.
Increasing robust pipeline of drug is expected to aid in the growth of the global Sjogren’s syndrome market. For instance, according to data published in July 2022, on Nation Institute of Medicine (NIH),states that a randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study is going on to assess the efficacy and safety of the drug Ianalumab in patients with Sjogren's syndrome and the estimated study completion date is in March 2026.
|Base Year:||2021||Market Size in 2022:||US$ 234.6 Mn|
|Historical Data for:||2017 to 2021||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||3.5%||2030 Value Projection:||US$ 308.4 Mn|
ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Novartis, MorphoSys, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO, Otsuka Pharmaceutical Co., Ltd., and Bridge Pharma Inc.
|Restraints & Challenges:||
Figure 2. Global Sjogren’s syndrome Market Share (%), by Drug, 2022
Global Sjogren’s syndrome Market: Restraint
Many of the Sjogren’s treatments that are currently available either only treat the symptoms or are viewed as ineffective by many patients. For instance, according to data published in September 2021, on Frontiers Media Journal, in a randomized trial, hydroxychloroquine (HCQ) did not significantly reduce the symptoms of primary Sjogren’s after 24 weeks of treatment when compared to placebo. In a similar other studies came to the same conclusion that hydroxychloroquine (HCQ) is not a successful treatment for primary Sjorgens.
Major players operating in the global Sjogren’s syndrome market include ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Novartis/MorphoSys, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO, Otsuka Pharmaceutical Co., Ltd., and Bridge Pharma Inc.
Sjogren’s syndrome is systematic autoimmune disorder which effect the entire body, along with complication such as, chronic pain, major organ involvement, profound fatigue, neuropathies and Sjogren’s syndrome zmphomas.
For the treatment of Sjogren’s syndrome different medication such as methotrexate available to manage the syndrome. Currently no single medication has been conclusively proven to treat the progression of Sjogren’s.
Antimalarial Quinolines, Cholinergic Agonists and Corticosteroids are the prescription drug used for the treatment of Sjogren’s.
Increasing prevalence of Sjogren’s syndrome is expected to drive the market growth during the forecast period.
For instance, according to the Sjogren’s Foundation 2021, around 3 to 4 million people in the U.S. suffer from Sjogren’s syndrome which is as common as rheumatoid arthritis (RA), and three times as common as systemic lupus erythematosus (SLE).
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.